Zacks Investment Research Upgrades 908 Devices (NASDAQ:MASS) to Hold

Zacks Investment Research upgraded shares of 908 Devices (NASDAQ:MASS) from a sell rating to a hold rating in a research note published on Wednesday, Zacks.com reports.

According to Zacks, “908 Devices Inc. is a purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis. It conducts research, designs and manufactures products of mass spectrometry, microfluidic separations, software automation and machine learning. 908 Devices Inc. is headquartered in Boston. “

MASS stock opened at $17.65 on Wednesday. The company has a quick ratio of 11.42, a current ratio of 12.06 and a debt-to-equity ratio of 0.12. 908 Devices has a 1 year low of $16.98 and a 1 year high of $79.60. The company has a fifty day simple moving average of $25.39 and a 200 day simple moving average of $31.02.

908 Devices (NASDAQ:MASS) last released its quarterly earnings data on Wednesday, November 3rd. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.04). The business had revenue of $12.50 million during the quarter, compared to analyst estimates of $12.03 million. 908 Devices had a negative net margin of 90.18% and a negative return on equity of 17.50%. The firm’s revenue was up 104.9% on a year-over-year basis. As a group, sell-side analysts forecast that 908 Devices will post -0.84 earnings per share for the current fiscal year.

In other 908 Devices news, VP John Kenneweg sold 10,000 shares of the business’s stock in a transaction on Monday, October 18th. The shares were sold at an average price of $32.22, for a total transaction of $322,200.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Joseph H. Iv Griffith sold 2,800 shares of the business’s stock in a transaction on Friday, November 5th. The stock was sold at an average price of $39.08, for a total transaction of $109,424.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 67,100 shares of company stock valued at $2,107,519. Company insiders own 51.10% of the company’s stock.

Several large investors have recently bought and sold shares of MASS. Swiss National Bank bought a new position in shares of 908 Devices during the 2nd quarter worth about $581,000. Rafferty Asset Management LLC bought a new position in shares of 908 Devices during the 2nd quarter worth about $3,454,000. Nicholas Investment Partners LP increased its holdings in shares of 908 Devices by 15.6% during the 2nd quarter. Nicholas Investment Partners LP now owns 357,858 shares of the company’s stock worth $13,867,000 after purchasing an additional 48,224 shares during the period. BlackRock Inc. increased its holdings in shares of 908 Devices by 198.3% during the 2nd quarter. BlackRock Inc. now owns 2,457,309 shares of the company’s stock worth $95,220,000 after purchasing an additional 1,633,500 shares during the period. Finally, Bank of New York Mellon Corp increased its holdings in shares of 908 Devices by 14.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 33,566 shares of the company’s stock worth $1,300,000 after purchasing an additional 4,291 shares during the period. Institutional investors own 57.34% of the company’s stock.

908 Devices Company Profile

908 Devices Inc develops and sells measurement devices for chemical and biochemical analysis in North America, Europe, the Middle East, Africa, and the Asia Pacific. It offers handheld and desktop mass spectrometry (Mass Spec) devices for the point-of-need applications in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets.

Further Reading: Compound Annual Growth Rate (CAGR)

Get a free copy of the Zacks research report on 908 Devices (MASS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for 908 Devices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 908 Devices and related companies with MarketBeat.com's FREE daily email newsletter.